GoodRx Holdings (GDRX) EPS (Weighted Average and Diluted) (2019 - 2026)

GoodRx Holdings has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting $0.0 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.0, down 88.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.06 (down 25.0% YoY), and the FY2025 annual result was $0.09, up 125.0% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.0 for Q1 2026 at GoodRx Holdings, down from $0.02 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.14 in Q2 2023 to a low of -$0.1 in Q3 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.0 (2026), against an average of $0.0.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 4285.92% in 2023, while the deepest fall reached 500.0% in 2023.
• GoodRx Holdings' EPS (Weighted Average and Diluted) stood at -$0.01 in 2022, then plunged by 500.0% to -$0.06 in 2023, then jumped by 133.33% to $0.02 in 2024, then slipped by 0.0% to $0.02 in 2025, then tumbled by 82.88% to $0.0 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.0 (Q1 2026), $0.02 (Q4 2025), and $0.0 (Q3 2025), per Business Quant data.